Aktie A3DUAC NEWAMSTERDAM PHARMA COMPANY N.V.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen NewAmsterdam Pharma Company N.V. Nasdaq

Aktien

A3DUAC

NL00150012L7

NAMS

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 26.06.2024 		% 5 Tage % 1. Jan.
19.75 USD +0.41% Intraday Chart für NewAmsterdam Pharma Company N.V. +15.43% +76.81%
11.06. NewAmsterdam Pharma erhält ein weiteres US-Patent zur Verlängerung des IP-Schutzes für Obicetrapib bis Juli 2043 MT
10.06. Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. NAMS Aktie
  4. A3DUAC Aktie
  5. Nachrichten NewAmsterdam Pharma Company N.V.
  6. Andere Sprachen